A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

March 6, 2025

Study Completion Date

March 6, 2025

Conditions
Nonsegmental Vitiligo With Genital Involvement
Interventions
DRUG

Ruxolitinib Cream

Ruxolitinib cream will be applied twice daily for upto 48 weeks

Trial Locations (13)

33075

Centre Hospitalier Universitaire de Bordeaux, Bordeaux

44124

Apex Clinical Research Center, Mayfield

78660

Austin Institute For Clinical Research Aicr Pflugerville, Pflugerville

90036

Vitiligo & Pigmentation Institute of Southern California, Los Angeles

94000

Hopital Henri Mondor Service de Dermatologie, Créteil

94538

Center For Dermatology Clinical Research, Inc, Fremont

48059-3526

Hamzavi Dermatology, Fort Gratiot

75024-4319

Innovative Dermatology: Legacy Medical Village, Plano

T2J 7E1

Dermatology Research Institute, Calgary

L4M 7G1

Simcomed Health Ltd, Barrie

K9J 5K2

Skin Centre For Dermatology, Peterborough

M3H 5Y8

Research Toronto, Toronto

06202

Chu Nice Hopital Archet 2, Nice

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY